ASH Clinical News January 2016 | Page 46

On Location 2015 ASH Annual Meeting

The End of an Era:
Does Transplant Still Have a Role in Multiple Myeloma Treatment?
With the rapid pace of drug discovery
in multiple myeloma (MM), the role of
autologous hematopoietic cell transplantation (AHCT) has been called into
question recently. However, according
to research presented at the 2015 ASH

Annual Meeting that compared patient
outcomes among patients treated with
conventional chemotherapy with or without AHCT, transplantation should still be
the standard of care in younger patients
with previously untreated MM.

“High-dose chemotherapy plus
autologous transplantation is considered
a standard of care for newly diagnosed
myeloma patients younger than 65 years of
age,” the authors of the study, led by Michel
Attal, MD, from the Institut Universitaire

du Cancer de Toulouse-Oncopole, Toulouse, France, wrote. However, “the high
complete response rate achieved with the
triplet combination of immunomodulatory drugs plus proteasome inhibitors
plus dexamethasone has led investigators

Bayer Access Solutions: Helpline assistance
and financial support for your patients
Bayer Access Solutions is here to help—navigating difficult insurance
issues, and providing financial support to eligible patients. Connect
with trained Case Specialists through the Bayer Access Solutions helpline.
Bayer Access Solutions Case Specialists can also help with enrollment in
the Bayer Access Solutions Co-pay Assistance Program. Eligible patients can
be covered for up to $12,000 in co-pay assistance, regardless of income.*
Call the Bayer Access Solutions helpline at 1-800-288-8374,
Monday–Friday, between 8:00 AM and 8:00 PM (ET).
Spanish-speaking Case Specialists are also available.
*People with private, commercial health insurance may receive Kogenate FS co-pay or

co-insurance assistance, based on eligibility requirements. The program is on a first-come,
first-served basis. Financial support is available for up to 12 months. Eligible patients can
re-enroll for additional 12-month courses. The program is not for patients receiving prescription
reimbursement under any federal-, state-, or government-funded insurance programs,
or where prohibited by law. All people who meet these criteria are encouraged to apply.

SELECTED IMPORTANT SAFETY INFORMATION (CONT’D)
■ Serious adverse reactions seen with Kogenate FS are systemic hypersensitivity reactions including
bronchospastic reactions and/or hypotension and anaphylaxis, and the development of high-titer
inhibitors necessitating alternative treatments to factor VIII.
■ The most common adverse reactions (≥4%) observed in clinical trials were inhibitor formation
in previously untreated and minimally treated patients, skin-related hypersensitivity reactions,
infusion site reactions, and central venous access device (CVAD) associated infections.
You are encouraged to report negative side effects of prescription drugs
to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.
For additional important risk and use information, please see brief summary on following pages.
References: 1. Kogenate® FS with Vial Adapter [package insert]. Whippany, NJ: Bayer
HealthCare LLC; 2015. 2. Manco-Johnson MJ, Kempton CL, Reding MT, et al. Randomized,
controlled, parallel-group trial of routine prophylaxis vs. on-demand treatment
with sucrose-formulated recombinant factor VIII in adults with severe hemophilia A
(SPINART) [published corrigendum appears in J Thromb Haemost. 2014;12(1):119-122].
J Thromb Haemost. 2013;11(6):1119-1127. 3. Data on file. Bayer HealthCare LLC; 2014.
Bayer, the Bayer Cross, and Kogenate are registered trademarks of Bayer.
© 2015 Bayer HealthCare Pharmaceuticals Inc. All rights reserved. Printed in USA.
10/15 PP-575-US-2107

B:16.75”

T:16.5”

S:15.25”